 |
Video Clips - broadband users | |
|
||
| Non nucleosides regimens | Rwanda TRAC | Uganda TASO | ||
|
||||
| News Highlights |
|
|
| Non-Nucleosides: Which and When? |
|
|
Two British doctors report ABUJA, Nigeria Two British physicians and HIV/AIDS experts were invited by MSD and St Stephen's AIDS Trust to share their data with more than 150 African doctors and other medical personnel who attended a Dec. 7, 2005 workshop at the International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA). Dr. Mark Nelson, a doctor at London's Chelsea & Westminster Hospital, and Dr. Martin Fisher, a physician at Brighton & Sussex University Hospitals, said they reached their conclusions by reviewing long-term studies performed all over the world. Surveys show that in the long run, AIDS patients are more likely to adhere to simplified treatment regimens based on NNRTIs. The doctor's choice within the NNRTI's class relies on the level of efficacy and toxicity. "It's not just about having drugs that work... but about having drugs people can take," Dr. Nelson said. Although the WHO recommendations are only guidelines, the Global Fund to Combat TB, AIDS and Malaria, which funds many anti-retroviral programs in developing countries, urges countries to purchase the least expensive drugs. Consequently, nevirapine, in either form, rather than efavirenz, is used much more widely in poor countries, including those in Africa. The African doctors reported diverse experiences with nevirapine and efavirenz in their own patients, but many shared a common concern about the development of nevirapine resistance and its shorter time to failure compared with efavirenz. They also raised the issue of the growing use of generics in internationally funded projects focusing on public health rather than on individual welfare. |
|
| Day 5 - PRESENTATION |
 |
